(E)-N-hydroxy-3-(4-(((2-(5-methoxy-1H-indol-3-yl)ethyl)amino)methyl)phenyl)acrylamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (E)-N-hydroxy-3-(4-(((2-(5-methoxy-1H-indol-3-yl)ethyl)amino)methyl)phenyl)acrylamide
• 英文别名: (E)-N-hydroxy-3-[4-[[2-(5-methoxy-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
• 化学式: C₂₁H₂₃N₃O₃
• 分子量: 365.432
• InChiKey: SKBXAZQJXDJNFI-RMKNXTFCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  86.4
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-甲氧基色胺 在 羟胺钾盐 、 水 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 2.08h， 生成 (E)-N-hydroxy-3-(4-(((2-(5-methoxy-1H-indol-3-yl)ethyl)amino)methyl)phenyl)acrylamide
  参考文献：
  名称：

  Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects In Vitro and Neuroprotective Effects in a Pharmacological Alzheimer’s Disease Mouse Model

  摘要：

  DOI：

  10.1021/acs.jmedchem.0c01940

文献信息

• Deacetylase inhibitors
  申请人：——

  公开号：US20030018062A1

  公开（公告）日：2003-01-23

  The present invention provides hydroxamate compounds which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.

  本发明提供了羟肟酸酯化合物，这些化合物是脱乙酰酶抑制剂。这些化合物适用于具有抗增殖特性的药物组合物。
• [EN] DEACETYLASE INHIBITORS<br/>[FR] INHIBITEURS DE DESACETYLASE
  申请人：NOVARTIS AG

  公开号：WO2002022577A2

  公开（公告）日：2002-03-21

  The present invention provides hydroxamate compounds of formula (I) which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.

  本发明提供了式（I）的羟肟酸化合物，这些化合物是去乙酰化酶抑制剂。这些化合物适用于具有抗增殖性质的药物组合物。
• DEACETYLASE INHIBITORS
  申请人：Remiszewski Stacy William

  公开号：US20080176849A1

  公开（公告）日：2008-07-24

  The present invention provides hydroxamate compounds which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.

  本发明提供了一种羟肟酸化合物，其为去乙酰化酶抑制剂。这些化合物适用于具有抗增殖性质的药物组合物。
• [EN] HETEROCYCLIC HYDROXAMIC ACID COMPOUND, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE D'ACIDE HYDROXAMIQUE, COMPOSITION PHARMACEUTIQUE ET APPLICATION ASSOCIÉES<br/>[ZH] 杂环羟肟酸类化合物及其药用组合物和应用
  申请人：GUANGZHOU GUARDIAN BIO TECH CO LTD

  公开号：WO2015085860A1

  公开（公告）日：2015-06-18

  本发明公开了一种具有通式I的杂环羟肟酸类化合物及其药学上可接受的酸或碱盐或立体异构体。本发明涉及的化合物及其药学上可接受的盐可以有效抑制多种肿瘤细胞的生长，并对组蛋白去乙酰化酶产生抑制作用，可用于制备抗肿瘤药物。
• <i>N</i>-Hydroxy-3-phenyl-2-propenamides as Novel Inhibitors of Human Histone Deacetylase with in Vivo Antitumor Activity:  Discovery of (2<i>E</i>)-<i>N</i>-Hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1<i>H</i>-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824)
  作者：Stacy W. Remiszewski、Lidia C. Sambucetti、Kenneth W. Bair、John Bontempo、David Cesarz、Nagarajan Chandramouli、Ru Chen、Min Cheung、Susan Cornell-Kennon、Karl Dean、George Diamantidis、Dennis France、Michael A. Green、Kobporn Lulu Howell、Rina Kashi、Paul Kwon、Peter Lassota、Mary S. Martin、Yin Mou、Lawrence B. Perez、Sushil Sharma、Troy Smith、Eric Sorensen、Francis Taplin、Nancy Trogani、Richard Versace、Heather Walker、Susan Weltchek-Engler、Alexander Wood、Arthur Wu、Peter Atadja

  DOI：10.1021/jm030235w

  日期：2003.10.1

  A series of N-hydroxy-3-phenyl-2-propenamides were prepared as novel inhibitors of human histone deacetylase (HDAC). These compounds were potent enzyme inhibitors, having IC(50)s < 400 nM in a partially purified enzyme assay. However, potency in cell growth inhibition assays ranged over 2 orders of magnitude in two human carcinoma cell lines. Selected compounds having cellular IC50 < 750 nM were tested for maximum tolerated dose (MTD) and for efficacy in the HCT116 human colon tumor xenograft assay. Four compounds having an MTD 100 mg/kg were selected for dose-response studies in the HCT116 xenograft model. One compound, 9 (NVP-LAQ824), had significant dose-related activity in the HCT116 colon and A549 lung tumor models, high MTD, and low gross toxicity. On the basis, in part, of these properties, 9 has entered human clinical trials in 2002.